I’m excited to launch the Longevity Biotech Atlas, a personal project mapping 700+ organizations across the aging and longevity ecosystem. Longevity biotech is moving fast. A lot of the public narrative has centered on GLP-1s, peptides, biohacking, and consumer health optimization. But beneath that, a much deeper ecosystem is forming: companies, labs, investors, and non-profits working on core technologies that will enable fundamentally new forms of measurement and rejuvenation. The field is growing quickly, but it is still hard to answer basic questions: Who is building what? Which areas are crowded? Which technologies are underexplored? Where should founders, scientists, investors, and operators be paying attention? To help make the space easier to navigate, I synthesized public information on 700+ organizations—ranging from therapeutics developers, diagnostics, investors, and more— into a single database. You can explore the atlas at the link in the comments. This is still an early version, and I’ll be adding more over time: new organizations, personal accounts, bookmarks, and better ways to track how the field is evolving. My hope is to build this out into a core tool for people trying to understand, build, fund, or work in longevity. If you’re interested in aging biology, biotech, investing, company formation, or the future of medicine, follow along. I’ll be sharing updates, maps of different subfields, and analyses of where the biggest opportunities and gaps may be. Let me know what you find useful!

What happens if you combine the TRIIM trial intervention with the recent DFI treatment Feng Zhang published? Both boosted different aspects of adaptive immune development and maintenance. The next step is clearly to put the two together!